<DOC>
	<DOCNO>NCT02598440</DOCNO>
	<brief_summary>This study evaluate participant-reported preference either ibandronate comparator drug woman postmenopausal osteoporosis . The anticipated time study treatment 6 month , target sample size 338 individual .</brief_summary>
	<brief_title>A Study Ibandronate ( Bonviva ) Patients With Post-Menopausal Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Ambulatory woman Diagnosis postmenopausal osteoporosis Women never receive bisphosphonate therapy , discontinue daily bisphosphonates least 3 month prior study entry Inability stand sit upright position great equal 60 minute Allergy bisphosphonates ; Previous current treatment weekly monthly bisphosphonates , daily bisphosphonates last 3 month prior study entry</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>